Seelos Therapeutics Inc (SEEL)

[eicoman]

the only way for Vitaros USA would be room temp with newer version of DDAIP, and big trials, which takes time to design and implement, 3 years, $50M, and what if the FDA says OK but limits the label to just severe ED, too much risk I think,

Ferring can do everything Apri wanted to do overseas with no resistence, room temp, rayva, other drugs, newer version of DDAIP with patent till 2031, there's alot there for Ferring,

if AGN bids low, Ferring will pay more, no question, the only reasons Allergan would go in is if they wanted the patents to do other drugs with DDAIP enantiomer, they have the cash to do the studies, we'll see